Paolo A Ascierto Selected Research

Antibodies

1/2024	Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
1/2023	A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19.
12/2020	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
1/2020	The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019.
12/2017	Anti-PD-1 and PD-L1 antibodies in metastatic melanoma.
2/2017	Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
1/2017	PD-L1 inhibitors in the pipeline: Promise and progress.
11/2015	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
2/2015	Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma.
6/2013	Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paolo A Ascierto Research Topics

Disease

291	Melanoma (Melanoma, Malignant) 04/2024 - 03/2003
148	Neoplasms (Cancer) 02/2024 - 01/2004
31	Neoplasm Metastasis (Metastasis) 03/2024 - 04/2006
24	Disease Progression 01/2023 - 11/2006
13	Brain Neoplasms (Brain Tumor) 01/2024 - 05/2012
8	Exanthema (Rash) 10/2023 - 03/2013
8	Fatigue 01/2023 - 01/2015
6	Skin Neoplasms (Skin Cancer) 02/2024 - 01/2013
6	COVID-19 03/2023 - 08/2021
6	Colitis 01/2021 - 05/2015
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2023 - 06/2016
5	Fever (Fevers) 01/2023 - 09/2016
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2022 - 03/2014
5	Hypertension (High Blood Pressure) 11/2022 - 01/2017
5	Pneumonia (Pneumonitis) 01/2022 - 08/2015
5	Body Weight (Weight, Body) 10/2019 - 01/2015
5	Neutropenia 01/2017 - 11/2012
4	Nausea 10/2023 - 01/2015
4	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 05/2010
4	Basal Cell Carcinoma (Rodent Ulcer) 12/2022 - 01/2015
4	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2018
4	Arthralgia (Joint Pain) 01/2020 - 01/2018
4	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 07/2016
3	Pain (Aches) 02/2024 - 06/2012
3	Uveal melanoma 01/2023 - 01/2017
3	Microsatellite Instability 01/2022 - 01/2020
3	Lymphatic Metastasis 11/2020 - 05/2015
3	Colonic Neoplasms (Colon Cancer) 11/2020 - 01/2018
3	Myalgia 10/2018 - 08/2015
3	Keratoacanthoma 01/2018 - 03/2014
3	Renal Cell Carcinoma (Grawitz Tumor) 10/2017 - 06/2016
2	Cytokine Release Syndrome 12/2023 - 03/2023
2	Type 2 Diabetes Mellitus (MODY) 10/2023 - 01/2023
2	Diarrhea 10/2023 - 01/2022
2	Dermatitis 10/2023 - 03/2013
2	Kidney Neoplasms (Kidney Cancer) 01/2023 - 08/2014

Drug/Important Bio-Agent (IBA)

79	IpilimumabIBA 01/2024 - 07/2011
59	NivolumabIBA 02/2024 - 12/2014
52	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2014
51	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2024 - 07/2012
47	VemurafenibIBA 04/2024 - 05/2012
45	Biomarkers (Surrogate Marker)IBA 01/2024 - 11/2006
43	pembrolizumabIBA 03/2024 - 02/2015
23	dabrafenibIBA 01/2023 - 05/2012
23	cobimetinibIBA 01/2023 - 07/2012
22	binimetinibIBA 04/2024 - 03/2013
18	encorafenibIBA 04/2024 - 07/2015
16	LigandsIBA 01/2023 - 07/2012
15	trametinibIBA 10/2023 - 03/2014
14	AntibodiesIBA 01/2024 - 10/2010
13	Monoclonal AntibodiesIBA 01/2022 - 11/2011
11	Dacarbazine (DIC)FDA LinkGeneric 11/2020 - 03/2014
10	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 05/2023 - 01/2018
10	B7-H1 AntigenIBA 01/2023 - 10/2017
9	Mitogen-Activated Protein KinasesIBA 10/2022 - 11/2015
8	atezolizumabIBA 01/2023 - 01/2017
8	AntigensIBA 10/2022 - 10/2010
8	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2005
7	Creatine Kinase (Creatine Phosphokinase)IBA 10/2023 - 03/2013
7	CytokinesIBA 03/2023 - 01/2016
7	InterferonsIBA 01/2021 - 10/2008
6	durvalumabIBA 01/2023 - 01/2017
6	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2004
5	Lipase (Acid Lipase)FDA Link 10/2023 - 11/2012
5	RNA (Ribonucleic Acid)IBA 01/2023 - 11/2018
5	Adenosine (Adenocard)FDA LinkGeneric 01/2022 - 01/2019
5	Programmed Cell Death 1 ReceptorIBA 01/2022 - 11/2018
5	Alanine Transaminase (SGPT)IBA 01/2021 - 04/2015
4	relatlimabIBA 10/2023 - 01/2022
4	Chimeric Antigen ReceptorsIBA 01/2023 - 11/2016
4	VaccinesIBA 01/2023 - 07/2012
4	spartalizumabIBA 01/2022 - 10/2020
4	Interleukin-2 (IL2)IBA 01/2021 - 04/2010
4	Proto-Oncogene Proteins B-rafIBA 01/2020 - 04/2014
3	tebentafuspIBA 01/2024 - 01/2023
3	bempegaldesleukinIBA 10/2023 - 10/2020
3	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2015
3	CTLA-4 AntigenIBA 01/2023 - 07/2015
3	EnzymesIBA 01/2022 - 10/2005
3	Circulating Tumor DNAIBA 01/2022 - 11/2018
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2020 - 03/2003
3	PlatinumIBA 01/2019 - 07/2016
3	HhAntag691IBA 12/2018 - 01/2015
3	Chemokine ReceptorsIBA 11/2017 - 04/2006
3	Interferon-alpha (Interferon Alfa)IBA 08/2014 - 08/2010
3	Arginine (L-Arginine)FDA Link 06/2011 - 10/2005
2	Bispecific AntibodiesIBA 12/2023 - 10/2022
2	tremelimumabIBA 01/2023 - 11/2011
2	Metformin (Glucophage)FDA LinkGeneric 01/2023 - 01/2023
2	MicroRNAs (MicroRNA)IBA 01/2023 - 02/2021

Therapy/Procedure

161	Therapeutics 03/2024 - 01/2006
97	Immunotherapy 04/2024 - 07/2011
26	Drug Therapy (Chemotherapy) 01/2023 - 05/2012
10	Neoadjuvant Therapy 01/2023 - 06/2012
7	Radiotherapy 04/2021 - 05/2012
5	Retreatment 01/2023 - 01/2014
5	Lymph Node Excision (Lymph Node Dissection) 10/2022 - 01/2018
5	Biological Therapy 08/2014 - 06/2010
4	Precision Medicine 01/2022 - 11/2016
3	Aftercare (After-Treatment) 05/2023 - 01/2018